University of Groningen
Challenges in the use of preventive cardiovascular medications in Indonesia and the Netherlands
Irawati, Sylvi
DOI:
10.33612/diss.146680004
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Irawati, S. (2020). Challenges in the use of preventive cardiovascular medications in Indonesia and the Netherlands. University of Groningen. https://doi.org/10.33612/diss.146680004
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Propositions
1. In an Asian population, the long-term, 20-year, risk of fatal cardiovascular disease (CVD) at least doubles the 10-year risk. (This thesis)
2. The risk ratio of long-term fatal stroke/fatal coronary heart disease (CHD) in an Asian population is 1.5:1. In contrast, in the Netherlands, the long-term fatal CHD risk is higher than the risk of fatal stroke. (This thesis)
3. In an Asian population, risk factors for long-term fatal CHD and fatal stroke are different with non-high-density-lipoprotein cholesterol (non-HDL-c) being associated with fatal CHD and hypertension being associated with fatal stroke. (This thesis)
4. In Indonesian patients with ST-elevation myocardial infarction (STEMI) treated with non-reperfusion therapy, adherence to guideline-recommended secondary preventive cardiovascular medications reduced the odds of in-hospital mortality. (This thesis)
5. In Indonesian patients with STEMI, a non-reperfusion strategy is an important predictor of suboptimal use of guideline-recommended secondary preventive cardiovascular medications. (This thesis)
6. The severity of Indonesian patients with STEMI on admission may predict adherence to guideline-recommended treatment. (This thesis)
7. Physicians seem to perceive the benefit-risk of using guideline-recommended medications for
STEMI-patients differently, hence a more personalized approach is required. (This thesis)
8. Strengthening the macro and microlevel factors influencing physicians’ behaviour on statin prescribing may lead to a more appropriate and collaborative intervention at the national level for optimising CVD prevention in Indonesia. (This thesis)
9. In the Dutch first-time statin users, the interaction between sex and the level of adherence to statin therapy is different between those on statin standard-dose and low-dose. (This thesis) 10. Honesty is the soul of business; honesty goes a long way. (Dutch proverbs; Samuel Smiles) 11. Transparency paves the way for well-informed decisions. (Sylvi Irawati)
